Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00533481

Enrollment

497

Registered

2007-09-21

Start date

2004-02-29

Completion date

2004-12-31

Last updated

2016-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

Study medicine will be given alone, or in combination with either sibutramine or orlistat, to obese subjects to compare the effect on body weight over a six month period.

Interventions

DRUGMK0557

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Men and women between the ages of 18-65 who are considered obese (have a body mass index between 30 and 43)

Exclusion criteria

* Subject has high blood pressure or is taking any high blood pressure medicine * History of psychiatric disorder, stroke, or heart disease

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026